ABSTRACT
Background: Mucormycosis is an opportunistic infection which has increased in the recent times of upsurge of cases of covid 19. Secondary infection by mucormycosis is noticed in individuals with low immune status, patients on steroid and oxygen therapy. Aims and Objectives:The aim was to analyse mucormycosis cases post covid19 as per age, gender, site of involvement, hospitalization status, site involvement and treatment outcome of patients. Materials and Methods: A retrospective study was conducted on specimens received in the Department of Pathology, over a period of 1 year in which 29 cases of mucormycosis were included. Specimens received in the laboratory were fixed in 10% formalin and submitted to detailed gross examination. Proper orientation in eye exenteration specimens and meticulous examination of the debridement specimens was done along with submission of representative sections in all the cases. Sections were then stained with H and E stain and special stain i.e., PAS and examined microscopically. Results: In this study, 29 patients over a period of 1 year are presented from a tertiary care center out of which 19 are males and 10 females, 82.75% patients with mucormycosis are covid 19 positive. Nasal cavity and maxillary sinus are most common sites involved. Survival rate in these patients is high due to early diagnosis and treatment. Conclusion: Hence, the present study emphasizes on the high incidence of mucormycosis in Covid 19 patients with predisposing factors mainly immunocompromised status, hospitalized patients. To prevent the occurrence of mucormycosis, early identification and further investigation of this fungus will significantly reduce the severity of the disease and mortality rate in Covid 19 affected patients.
ABSTRACT
How to cite this article: Sampley S, Bhasin D, Singh H, Mishra S. Cerebral Aspergillosis Complicating COVID Recovery. Indian J Crit Care Med 2022;26(4):535–536.
ABSTRACT
How to cite this article: Sampley S, Bhasin D, Singh H, Mishra S. Cerebral Aspergillosis Complicating COVID Recovery. Indian J Crit Care Med 2022;26(4):535-536.
ABSTRACT
Since 1988, when World Health Organization (WHO) Member States and partners launched the Global Polio Eradication Initiative, the number of wild poliovirus (WPV) cases has declined from 350,000 in 125 countries to 176 in only two countries in 2019 (1). The Global Commission for the Certification of Poliomyelitis Eradication (GCC) declared two of the three WPV types, type 2 (WPV2) and type 3 (WPV3), eradicated globally in 2015 and 2019, respectively (1). Wild poliovirus type 1 (WPV1) remains endemic in Afghanistan and Pakistan (1). Containment under strict biorisk management measures is vital to prevent reintroduction of eradicated polioviruses into communities from poliovirus facilities. In 2015, Member States committed to contain type 2 polioviruses (PV2) in poliovirus-essential facilities (PEFs) certified in accordance with a global standard (2). Member states agreed to report national PV2 inventories annually, destroy unneeded PV2 materials, and, if retaining PV2 materials, establish national authorities for containment (NACs) and a PEF auditing process. Since declaration of WPV3 eradication in October 2019, these activities are also required with WPV3 materials. Despite challenges faced during 2019-2020, including the coronavirus disease 2019 (COVID-19) pandemic, the global poliovirus containment program continues to work toward important milestones. To maintain progress, all WHO Member States are urged to adhere to the agreed containment resolutions, including officially establishing legally empowered NACs and submission of PEF Certificates of Participation.